Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
53 hedge funds and large institutions have $115M invested in Regulus Therapeutics in 2014 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 26 increasing their positions, 14 reducing their positions, and 8 closing their positions.
2,300% more call options, than puts
Call options by funds: $48K | Put options by funds: $2K
86% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 55 → 53 (-2)
10% less capital invested
Capital invested by funds: $128M → $115M (-$13.1M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.39M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$292K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$261K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$236K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$229K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.04M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$558K |
| 3 |
Jennison Associates
New York
|
-$271K |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$227K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$180K |
RGLS Hedge Fund Activity: Q2 2014 in Review
53 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2014, worth a combined $115M — down 10% from $128M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of RGLS and 6 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 26 added.
The largest buyer was Wellington Management Group, adding an estimated $1.39M. The largest seller was Millennium Management, exiting entirely with an estimated $1.04M sold.
- 53 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2014, down from 55 in Q1 2014.
- Funds reported $115M of Regulus Therapeutics stock for Q2 2014, down 10% quarter-over-quarter.
- 6 funds opened new Regulus Therapeutics positions in Q2 2014 and 8 closed out, a net change of -2 holders.
- The largest Regulus Therapeutics buyer in Q2 2014 was Wellington Management Group, an estimated $1.39M added.
- The largest Regulus Therapeutics seller in Q2 2014 was Millennium Management, an estimated $1.04M sold.
Based on aggregated 13F filings for Q2 2014.